Reata is also currently developing bardoxolone methyl in 4 other rare forms of CKD for which there are unmet needs:
- Autosomal dominant polycystic kidney disease (ADPKD)
- IgA nephropathy (IgAN)
- Type 1 diabetic CKD (T1D CKD)
- Focal segmental glomerulosclerosis (FSGS)
Combined, these rare diseases represent a patient population of more than 500,000. The clinical activity observed in patients with ADPKD, IgAN, and T1D CKD suggests that bardoxolone methyl targets the final common pathway of kidney function loss relevant to many forms of CKD.
Chronic inflammation is a common mechanism underlying the development and progression of several CKD states. Inflammatory mediators can cause sustained injury that spreads from the glomerulus to the tubules, leading to inflammation, fibrosis, progressive loss of kidney function and ESRD.1,6 Reata is studying the effects of bardoxolone methyl to intervene in the inflammatory process and help preserve kidney function.